Kao L C, Durand D J, McCrea R C, Birch M, Powers R J, Nickerson B G
Division of Neonatology, Children's Hospital, Oakland, California 94609.
J Pediatr. 1994 May;124(5 Pt 1):772-81. doi: 10.1016/s0022-3476(05)81373-3.
To determine whether long-term oral diuretic therapy would improve the pulmonary function of preterm infants with bronchopulmonary dysplasia.
Randomized, double-blind, placebo-controlled study.
Level III intensive care nursery.
We randomly selected 43 stable patients with oxygen-dependent bronchopulmonary dysplasia to receive either orally administered spironolactone and chlorothiazide or placebo. These drugs were continued until the patients no longer required supplemental oxygen. Both groups received furosemide as needed.
Each infant had pulmonary function tests at study entry, 4 weeks after study entry, 1 week and 8 weeks after being weaned to room air and off study drugs, and at 1 year of corrected age. Pulmonary function tests include dynamic pulmonary compliance, airway resistance, thoracic gas volume, and maximal expiratory flow at functional residual capacity; most of the infants had functional residual capacity measured. Between the first and second pulmonary function tests (while the infants were receiving diuretic or placebo), the infants in the diuretic group had a significant improvement in dynamic pulmonary compliance (46%; p < 0.001) and airway resistance (31%; p < 0.05); there were no changes in compliance or resistance in the placebo group. Although patients in both the diuretic and the placebo groups required progressively less supplemental oxygen, by 4 weeks after study entry the patients in the diuretic group needed less supplemental oxygen than did those in the placebo group (p < 0.01). There were no significant differences in results of serial pulmonary function tests in either group after discontinuation of diuretic therapy. Despite the significant differences in pulmonary function between the two groups, there was no significant difference between them in the total number of days that supplemental oxygen was required. Significantly more infantsin the placebo group received more than 10 doses of furosemide on an as-needed basis.
Long-term diuretic therapy in stable infants with oxygen-dependent bronchopulmonary dysplasia, after extubation, improves their pulmonary function and decreases their fractional inspired oxygen requirement, but does not decrease the number of days that they require supplemental oxygen. The improvement in pulmonary function associated with diuretic therapy is not maintained after treatment is discontinued.
确定长期口服利尿剂治疗是否能改善支气管肺发育不良早产儿的肺功能。
随机、双盲、安慰剂对照研究。
三级重症监护病房。
我们随机选取43例依赖氧气的稳定支气管肺发育不良患者,给予口服螺内酯和氢氯噻嗪或安慰剂。这些药物持续使用直至患者不再需要补充氧气。两组均按需使用呋塞米。
每位婴儿在研究开始时、研究开始后4周、断奶至室内空气且停用研究药物后1周和8周以及矫正年龄1岁时进行肺功能测试。肺功能测试包括动态肺顺应性、气道阻力、胸腔气体容积和功能残气量时的最大呼气流量;大多数婴儿测量了功能残气量。在第一次和第二次肺功能测试之间(婴儿接受利尿剂或安慰剂治疗时),利尿剂组婴儿的动态肺顺应性显著改善(46%;p<0.001),气道阻力改善(31%;p<0.05);安慰剂组的顺应性或阻力无变化。尽管利尿剂组和安慰剂组的患者所需补充氧气量逐渐减少,但在研究开始后4周,利尿剂组患者所需补充氧气量比安慰剂组少(p<0.01)。停用利尿剂治疗后,两组系列肺功能测试结果无显著差异。尽管两组肺功能存在显著差异,但所需补充氧气的总天数无显著差异。安慰剂组中,显著更多的婴儿按需接受了超过10剂的呋塞米。
拔管后,对依赖氧气的稳定支气管肺发育不良婴儿进行长期利尿剂治疗可改善其肺功能,降低其吸入氧分数需求,但不会减少其所需补充氧气的天数。利尿剂治疗相关的肺功能改善在治疗停止后无法维持。